blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2919014

EP2919014 - Composition for use as an abnormal coagulation control plasma in in vitro assays [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.06.2018
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  14.07.2017
FormerGrant of patent is intended
Status updated on  07.05.2017
FormerExamination is in progress
Status updated on  06.01.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Grifols, S.A.
C/Jesús y María, 6
08022 Barcelona / ES
[2015/38]
Inventor(s)01 / SEGUI BORRELL, JOSE
C/ LLEIDA 39, 4t - 1.
08004 BARCELONA / ES
02 / MARTORELL PENA, DANIEL
RAMON MIQUEL I PLANES 10,AT.1
08034 BARCELONA / ES
 [2015/38]
Representative(s)Durán-Corretjer, S.L.P.
Còrsega, 329
(Paseo de Gracia/Diagonal)
08037 Barcelona / ES
[2015/38]
Application number, filing date15382091.503.03.2015
[2015/38]
Priority number, dateES2014003034313.03.2014         Original published format: ES 201430343
[2015/38]
Filing languageES
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2919014
Date:16.09.2015
Language:EN
[2015/38]
Type: B1 Patent specification 
No.:EP2919014
Date:16.08.2017
Language:EN
[2017/33]
Search report(s)(Supplementary) European search report - dispatched on:EP01.07.2015
ClassificationIPC:G01N33/86
[2015/38]
CPC:
G01N33/96 (EP,CN,US); C12Q1/37 (ES); C07C65/28 (ES);
G01N2496/05 (EP,US); Y10T436/106664 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/46]
Former [2015/38]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:Zusammensetzung für die Verwendung als abnormes Koagulationskontrolplasma in in vitro Assays[2015/38]
English:Composition for use as an abnormal coagulation control plasma in in vitro assays[2015/38]
French:Composition pour l'utilisation comme un plasma de contrôle de coagulation anormale dans des essais in vitro[2015/38]
Examination procedure30.09.2015Amendment by applicant (claims and/or description)
01.10.2015Examination requested  [2015/46]
01.04.2016Despatch of a communication from the examining division (Time limit: M04)
02.05.2016Reply to a communication from the examining division
26.07.2016Despatch of a communication from the examining division (Time limit: M04)
30.09.2016Reply to a communication from the examining division
04.01.2017Despatch of a communication from the examining division (Time limit: M04)
03.02.2017Reply to a communication from the examining division
08.05.2017Communication of intention to grant the patent
03.07.2017Fee for grant paid
03.07.2017Fee for publishing/printing paid
03.07.2017Receipt of the translation of the claim(s)
Opposition(s)17.05.2018No opposition filed within time limit [2018/30]
Fees paidRenewal fee
07.03.2017Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.03.2015
AL16.08.2017
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
HR16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
MK16.08.2017
PL16.08.2017
PT16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
LU03.03.2018
MT03.03.2018
[2020/34]
Former [2020/31]HU03.03.2015
CY16.08.2017
CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
HR16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
MK16.08.2017
PL16.08.2017
PT16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
LU03.03.2018
MT03.03.2018
Former [2020/30]HU03.03.2015
CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
HR16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
PL16.08.2017
PT16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
LU03.03.2018
MT03.03.2018
Former [2020/28]CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
PL16.08.2017
PT16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
LU03.03.2018
MT03.03.2018
Former [2020/08]CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
LU03.03.2018
MT03.03.2018
Former [2019/04]CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
LU03.03.2018
Former [2018/52]CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
MC16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/40]CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SI16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/25]CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SK16.08.2017
SM16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/23]CZ16.08.2017
DK16.08.2017
EE16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
PL16.08.2017
RO16.08.2017
RS16.08.2017
SE16.08.2017
SK16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/21]CZ16.08.2017
DK16.08.2017
FI16.08.2017
LT16.08.2017
LV16.08.2017
PL16.08.2017
RS16.08.2017
SE16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/12]FI16.08.2017
LT16.08.2017
LV16.08.2017
PL16.08.2017
RS16.08.2017
SE16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/11]FI16.08.2017
LT16.08.2017
PL16.08.2017
RS16.08.2017
SE16.08.2017
BG16.11.2017
NO16.11.2017
GR17.11.2017
IS16.12.2017
Former [2018/09]FI16.08.2017
LT16.08.2017
SE16.08.2017
NO16.11.2017
Former [2018/08]FI16.08.2017
LT16.08.2017
NO16.11.2017
Former [2018/07]LT16.08.2017
NO16.11.2017
Documents cited:Search[A] WO0107921  (MEDICAL ANALYSIS SYSTEMS INC et al.) [A] 1-11
 [I]   SONG WANG ET AL: "The anticoagulant ability of ferulic acid and its applications for improving the blood compatibility of silk fibroin; The anticoagulant ability of FA and improving the blood compatibility of SF", BIOMEDICAL MATERIALS, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 3, no. 4, 1 December 2008 (2008-12-01), pages 44106, XP020148410, ISSN: 1748-605X, DOI: 10.1088/1748-6041/3/4/044106 [I] 11 * the whole document, in particular "Abstract" and p.2, right-hand column, 2nd paragraph *

DOI:   http://dx.doi.org/10.1088/1748-6041/3/4/044106
 [I]   TANG Y P ET AL: "Effects of Aromatic Acids on Stimulating Blood Circulation and Removing Blood Stasis", WORLD SCIENCE AND TECHNOLOGY,, vol. 10, no. 4, 1 August 2008 (2008-08-01), pages 38 - 42, XP026644689, ISSN: 1876-3553, [retrieved on 20080801], DOI: 10.1016/S1876-3553(09)60019-3 [I] 11 * the whole document, in partiuclar Fig. 2; p.40, left-hand column, 1st paragraph and p.41, left-hand column, 2nd paragraph *

DOI:   http://dx.doi.org/10.1016/S1876-3553(09)60019-3
 [I]   WEE JAE JOON ET AL: "Identification of Anticoagulant Components in Korean Red Ginseng", JOURNAL OF GINSENG RESEARCH, vol. 34, no. 4, December 2010 (2010-12-01), pages 355 - 362, XP002741001, ISSN: 1226-8453 [I] 11 * the whole document *

DOI:   http://dx.doi.org/10.5142/jgr.2010.34.4.355
 [A]   MONIEN B H ET AL: "Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 14, no. 23, 1 December 2006 (2006-12-01), pages 7988 - 7998, XP027992231, ISSN: 0968-0896, [retrieved on 20061201] [A] 1-11
ExaminationUS2001004641
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.